R&D Trends

UCLA receives $4 million from Eli and Edythe Broad Foundation

Wednesday, May 14, 2014 01:05 PM

Two new gifts from the Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two research centers.

More... »

WIRB Copernicus Group

Debiopharm Group, Yale extend collaboration for MIF inhibitors

Monday, May 12, 2014 12:23 PM

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, has signed a new license and research agreement with Yale University for the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

More... »

CRF Health eCOA webinar series

Evotec, Eternygen collaborate for novel metabolic disease therapy

Monday, May 12, 2014 12:19 PM

Evotec, a drug discovery alliance and development partnership company, and Eternygen, a Berlin-based, privately owned biopharmaceutical company, are collaborating to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and experience in drug discovery and preclinical development.

More... »

Moffitt Cancer Center, Vermillion collaborate

Friday, May 9, 2014 12:32 PM

The Moffitt Cancer Center in Tampa, Fla., and Austin-based Vermillion have announced a research collaboration, launching a study to produce clinical and economic data to support a new value-based practice model that may improve survival, quality of life and cost-effectiveness of care for patients with ovarian cancer.

More... »

Triesta Sciences, Strand Life Sciences launch Strand-Triesta Center for Cancer Genomics

Friday, May 9, 2014 12:31 PM

Triesta Sciences, a unit of HealthCare Global (HCG) Enterprises, is partnering for cancer genomics with Strand Life Sciences, a provider of clinical genomics, to set up a new center for genomics called Strand-Triesta Center for Cancer Genomics (Strand-Triesta) to make genomics-based diagnostics effective, accessible and affordable. Strand-Triesta will enable the world's largest adoption of genomics-based tumor profiling for HCG patients. HCG will adopt the Strand-Triesta advanced cancer diagnostics as a new standard-of-care.

More... »

Report: New thinking needed for funding, development of future medicines

Thursday, May 8, 2014 01:20 PM

Pharmaceutical scientists are calling for a new covenant to be developed between the pharmaceutical industry and wider society, including government, to accelerate and incentivize the development of new types of tailored medicines and treatments.

More... »

PhRMA: More than 100 medicines for mental health disorders in development

Wednesday, May 7, 2014 01:29 PM

America’s biopharmaceutical research companies currently are developing 119 novel new medicines to help improve the lives of the estimated 61.5 million Americans affected by mental health disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »

FDA launches Center of Excellence in drug development, regulation at UCSF

Wednesday, May 7, 2014 01:26 PM

The FDA has selected UC San Francisco (UCSF) as the site of a new regulatory science center on the West Coast. The center, which will be a joint effort between scientists in the UCSF School of Pharmacy and Stanford University, aims to spur innovative approaches in drug development that will support the FDA's ability to evaluate and approve safe and effective new medications.

More... »

Canadian government invests $7.3M to encourage genetics cancer research

Wednesday, May 7, 2014 01:15 PM

The government of Canada has announced $7.3 million in funding for collaboration, both in Canada and internationally, to develop tools that can effectively manipulate vast amounts of data to help find cures for cancer.

More... »

Study: $260M spent on Women’ Health Initiative trial has saved $37B in healthcare costs over 10 years

Tuesday, May 6, 2014 12:34 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Critics opposed to hefty government research spending may think twice after learning that a 15-year, $260 million federally funded study—known as the Women’s Health Initiative (WHI) estrogen plus progestin clinical trial—showed changes in medical practice stemming from the trial provided a net economic return of $37.1 billion over a 10-year period—or about $140 on every federal dollar invested in the trial.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs